Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 39 of the 65 sources its claims cite were checked for support.

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Open access

Abstract

Glucagon-like peptide-1 receptor agonists act via appetite suppression and caloric restriction. These treatments can result in significant muscle loss, likely due to evolutionary mechanisms protecting against food scarcity as muscle is a major energy utilizer. One mechanism that reduces muscle mass involves activation of type II activin receptors, ActRIIA/B, which yield profound muscle growth in humans when blocked. We previously demonstrated GDF8, also known as myostatin, and activin A are the two major ActRIIA/B ligands mediating muscle minimization. Here, we report that dual blockade can also prevent muscle loss associated with glucagon-like peptide-1 receptor agonists – and even increase muscle mass – in both obese mice and non-human primates; moreover, this muscle preservation enhances fat loss and is metabolically beneficial. These data raise the possibility that supplementing glucagon-like peptide-1 receptor agonist treatment with GDF8 and activin A blockade could greatly improve the quality of weight loss during the treatment of obesity in humans. Myostatin and activin A are the two primary negative regulators of muscle mass. Blocking these circulating ligands during GLP-1 therapy induces improved body composition through preservation of lean mass and enhanced fat mass loss in obese primates.

Overview

CoChat Summary

TL;DR

In obese male mice and obese cynomolgus monkeys, blocking GDF8 (myostatin) and activin A alongside semaglutide preserved or increased lean mass while also increasing fat loss. The authors argue this could improve the quality of GLP-1–induced weight loss by reducing muscle loss and improving metabolic outcomes.

Key findings

  • In obese mice, semaglutide caused significant lean mass loss, whereas semaglutide plus α-MSTN/α-ActA protected against that loss and produced a significant increase in lean mass.
  • In the mouse study, semaglutide plus α-MSTN/α-ActA caused markedly greater fat loss than semaglutide alone, described as “almost twice” the fat loss seen with semaglutide alone.
  • In obese cynomolgus monkeys, after α-MSTN/α-ActA was added at week 2, the semaglutide + antibody arm diverged from semaglutide alone with progressively greater fat loss and progressively greater increases in lean mass.
  • The monkey study also reported beneficial changes in HbA1c%, LDL-C, and HDL-C across treated arms, with the semaglutide + α-MSTN + α-ActA arm showing the biggest beneficial changes.

Methods

  • Two diet-induced obese mouse studies in male C57Bl/6 mice tested semaglutide, α-MSTN/α-ActA, both together, or controls; body composition was tracked by qNMR, and liver fat/triglycerides were assessed in the first study.
  • A 20-week study in obese male cynomolgus monkeys (final cohort 40 animals, 10 per group) tested semaglutide with or without α-MSTN/α-ActA; primary endpoints were body weight and body composition by DXA, with food intake, HbA1c%, and lipid profiles also measured.
  • The main analysis used one-way or two-way repeated measures ANOVA; the paper states no sample size calculations were performed.

Limitations

  • Stated by the paper: the combination was tested only in male mice and male monkeys, so female GLP-1 combination effects were not directly tested here.
  • Stated by the paper: no sample size calculation was performed for any study.
  • Evident from the text: the report is preclinical and does not directly test the combination in humans with obesity in this paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-025-59485-9

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Myostatin and activin A blockade induce additive fat mass loss with semaglutide in DIO mice. Male diet-induced, obese C57Bl/6 mice were treated for four weeks with control antibody (white circles, n = 7), Sema (blue squares, n = 8), α-MSTN/ (orange triangles, n = 7) or Sema + α-MSTN/α-ActA (purple diamonds, n = 8). a Body weight, b lean mass, and c fat mass in percent change from baseline as measured by EchoMRI. d, e Terminal liver fat area and triglyceride content. f Representative H&E images from each group. Data are presented as mean ± SEM. a–c * P < 0.05 vs. vehicle, # P < 0.05 vs. Sema, ^ P < 0.05 vs. α-MSTN/α-ActA by two-way RM ANOVA. d * P < 0.05 vs. vehicle, # P < 0.01 vs. Sema, ^ P < 0.01 vs. α-MSTN/α-ActA by one-way ANOVA. e * P < 0.05, ** P < 0.01, **** P < 0.0001 vs. vehicle by one-way ANOVA. α-MSTN: anti-myostatin antibody, α-ActA: anti-activin a antibody, sema: semaglutide.
Fig. 1 Myostatin and activin A blockade induce additive fat mass loss with semaglutide in DIO mice. Male diet-induced, obese C57Bl/6 mice were treated for four weeks with control antibody (white circles, n = 7), Sema (blue squares, n = 8), α-MSTN/ (orange triangles, n = 7) or Sema + α-MSTN/α-ActA (purple diamonds, n = 8). a Body weight, b lean mass, and c fat mass in percent change from baseline as measured by EchoMRI. d, e Terminal liver fat area and triglyceride content. f Representative H&E images from each group. Data are presented as mean ± SEM. a–c * P < 0.05 vs. vehicle, # P < 0.05 vs. Sema, ^ P < 0.05 vs. α-MSTN/α-ActA by two-way RM ANOVA. d * P < 0.05 vs. vehicle, # P < 0.01 vs. Sema, ^ P < 0.01 vs. α-MSTN/α-ActA by one-way ANOVA. e * P < 0.05, ** P < 0.01, **** P < 0.0001 vs. vehicle by one-way ANOVA. α-MSTN: anti-myostatin antibody, α-ActA: anti-activin a antibody, sema: semaglutide.CC BY-NC-ND · PubMed Central
Fig. 2 Myostatin and activin A blockade induce additive fat mass loss with GLP-1R agonism in obese non-human primates. Male, obese cynomolgus monkeys were treated for 20 weeks with control antibody (white circles, n = 10), Sema (blue squares, n = 9), α-MSTN/α-ActA (orange triangles, n = 8) or Sema + α-MSTN/α-ActA (purple diamonds, n = 10). a Body weight, expressed as percent change from baseline. b Daily total energy intake (TEI) expressed as a seven-day average in kilocalories (kcal) for each group. Each time point represents the daily average of the previous seven days ± SEM. c–e Total mass, fat mass, and lean mass measured by DXA scanning and expressed as percent change from baseline. Data are presented as mean ± SEM. Panels a-e: * P < 0.05 vs. vehicle, # P < 0.05 vs. Sema, ^ P < 0.05 vs. α-MSTN + α-ActA, $ P < 0.05 vs. Sema + α-MSTN + α-ActA, + P < 0.05 vs. baseline for the last timepoint of each group. Stats by two-way repeated measures ANOVA. α-MSTN: anti-myostatin antibody, α-ActA: anti-activin a antibody, sema: semaglutide, DXA dual energy x-ray absorptiometry.
Fig. 2 Myostatin and activin A blockade induce additive fat mass loss with GLP-1R agonism in obese non-human primates. Male, obese cynomolgus monkeys were treated for 20 weeks with control antibody (white circles, n = 10), Sema (blue squares, n = 9), α-MSTN/α-ActA (orange triangles, n = 8) or Sema + α-MSTN/α-ActA (purple diamonds, n = 10). a Body weight, expressed as percent change from baseline. b Daily total energy intake (TEI) expressed as a seven-day average in kilocalories (kcal) for each group. Each time point represents the daily average of the previous seven days ± SEM. c–e Total mass, fat mass, and lean mass measured by DXA scanning and expressed as percent change from baseline. Data are presented as mean ± SEM. Panels a-e: * P < 0.05 vs. vehicle, # P < 0.05 vs. Sema, ^ P < 0.05 vs. α-MSTN + α-ActA, $ P < 0.05 vs. Sema + α-MSTN + α-ActA, + P < 0.05 vs. baseline for the last timepoint of each group. Stats by two-way repeated measures ANOVA. α-MSTN: anti-myostatin antibody, α-ActA: anti-activin a antibody, sema: semaglutide, DXA dual energy x-ray absorptiometry.CC BY-NC-ND · PubMed Central
Fig. 3 Addition of Myostatin and activin A blockade to semaglutide further improves glucose, HbA1c%, LDL-C and HDL-C. Male, obese cynomolgus monkeys were treated for 20 weeks with control antibody (white circles, n = 10), Sema (blue squares, n = 9), α-MSTN/α-ActA (orange triangles, n = 8), or Sema + α-MSTN/α-ActA (purple diamonds, n = 10). Clinical chemistry results for a fasting glucose b hemoglobin A1c (HbA1c%), c low-density lipoprotein (LDL-C), and d high-density lipoprotein (HDL-C). Blood for all values was taken in the morning before breakfast. All data points are mean ± SEM. * P < 0.05 vs. vehicle, # P < 0.05 vs. Sema, ^ P < 0.05 vs. α-MSTN + α-ActA, + P < 0.05 vs. baseline for the last timepoint of each group. Stats by two-way RM ANOVA. α-MSTN: anti-myostatin antibody, α-ActA: anti-activin a antibody, sema: semaglutide, DXA dual energy x-ray absorptiometry.
Fig. 3 Addition of Myostatin and activin A blockade to semaglutide further improves glucose, HbA1c%, LDL-C and HDL-C. Male, obese cynomolgus monkeys were treated for 20 weeks with control antibody (white circles, n = 10), Sema (blue squares, n = 9), α-MSTN/α-ActA (orange triangles, n = 8), or Sema + α-MSTN/α-ActA (purple diamonds, n = 10). Clinical chemistry results for a fasting glucose b hemoglobin A1c (HbA1c%), c low-density lipoprotein (LDL-C), and d high-density lipoprotein (HDL-C). Blood for all values was taken in the morning before breakfast. All data points are mean ± SEM. * P < 0.05 vs. vehicle, # P < 0.05 vs. Sema, ^ P < 0.05 vs. α-MSTN + α-ActA, + P < 0.05 vs. baseline for the last timepoint of each group. Stats by two-way RM ANOVA. α-MSTN: anti-myostatin antibody, α-ActA: anti-activin a antibody, sema: semaglutide, DXA dual energy x-ray absorptiometry.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

16 Valid · 3 Not valid · 7 Not checked · 59 Own results and interpretations

36 more claims · 6 with their cited sources checked

Create a free account to see all 85 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 23
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 63 references

Cited by

See all 53

Metadata

Authors
Mastaitis, J. W., Gomez, D., Raya, J. G., Li, D., Min, S., Stec, M., Kleiner, S., McWilliams, T., Altarejos, J. Y., Murphy, A. J., Yancopoulos, G. D., & Sleeman, M. W.
Affiliations
Regeneron (United States) (US)
Corresponding author
Sleeman, Mark W.
Venue
Nature Communications
Published
2025-05-13
Volume
16
Issue
1
Pages
4377-4377
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4410325205
Cited by
53
References
63
Citations by year
2026: 34 · 2025: 19
FWCI
15.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Regeneron Pharmaceuticals (N/A)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
myostatin, activin A, GLP-1 receptor agonists, muscle mass loss, obesity, fat loss, body composition, muscle mass preservation, non-human primates, weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Adipose Tissue, Animals, Humans, Male, Mice, Inbred C57BL, Mice, Obese, Obesity, Muscle, Skeletal, Activins, Activin Receptors, Type II, Mice, Glucagon-Like Peptide 1, Myostatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates. https://app.cochat.ai/papers/10.1038/s41467-025-59485-9
The paper
Mastaitis, J. W., Gomez, D., Raya, J. G., Li, D., Min, S., Stec, M., Kleiner, S., McWilliams, T., Altarejos, J. Y., Murphy, A. J., Yancopoulos, G. D., & Sleeman, M. W. (2025). GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nature Communications. https://doi.org/10.1038/s41467-025-59485-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.